Variant-of-concern-attributable health and health system-related outcomes: a population-level propensity-score matched cohort study.

- Aysegul Erman MSc PhD,² Sharmistha Mishra MD MSc PhD,²
PhD(c),¹ David Naimark MD MSc,⁴ Beate Sander RN MBA MEc
Author affiliations:
1. Toronto Health Economics and Technology Assessment (
1. Network, Toronto, Can Kali A Barrett MD MSc,"
"Dev PhD¹
THETA) Collaborative, Ur
Canada
versity of Toronto, Toror
"ntre, Toronto, Canada Stephen Mac
Niversity Health
No, Canada PhD(c),⁺
Author
1. Torc
2. Dep
2. Dep
3. Inte
4. Dep David Naimark MD MSc,
affiliations:
anto Health Economics an
work, Toronto, Canada
artment of Medicine, Unit
rdepartmental Division of
artment of Medicine, Sun Beate Sander RN MBA MEcDev PhD⁺
d Technology Assessment (THETA) Co
y Health Toronto, Toronto, Canada
Critical Care Medicine, University of
nybrook Health Sciences Centre, Torc $\begin{bmatrix} 1 \\ 2 \end{bmatrix}$ Author armiations:
1. Toronto Health
Network, Toron
2. Department of I
4. Department of I
*Corresponding Author
-
-
-

Network, Toronto, Canada

2. Department of Medicine, Unity Health Toronto, Toronto, Canada

3. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada

4. Department of Medicine, Sunnyb Department of Medicine, U
Interdepartmental Division
Department of Medicine, S
rresponding Author: Ayseg
Into Health Economics and
Inology Assessment (THET*I*
Jersity Health Network 3. Interdepartmental Division of Critical Care Medicine, University of
4. Department of Medicine, Sunnybrook Health Sciences Centre, Tor
*Corresponding Author: Aysegul Erman
Toronto Health Economics and
Technology Assessme 3. Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
3. Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada
***Corresponding Author**: Aysegul Erman
Toronto Health Economics an *Corresponding Author: Aysegul Erman
Toronto Health Economics and
Technology Assessment (THETA) Collaborative
University Health Network
Toronto General Hospital
Eaton Building, 10th Floor,
200 Elizabeth Street, Toronto, ON **Toronto Health Economics and Technology Assessment (THETA) Collabo University Health Network**
Toronto General Hospital
Technology Assessment (THETA) Collabo
University Health Network
Toronto General Hospital
Eaton Buildin Technology Assessment (THETA
University Health Network
Toronto General Hospital
Eaton Building, 10th Floor,
200 Elizabeth Street, Toronto, (
E-mail: aysegul.erman@mail.ut
A hstract Technology March Network
Toronto General Hospital
Eaton Building, 10th Floor,
200 Elizabeth Street, Toronto, ON M5G 2C4
E-mail: aysegul.erman@mail.utoronto.ca
Abstract Toronto General Hospital
Eaton Building, 10th Floor,
200 Elizabeth Street, Toron
E-mail: aysegul.erman@ma
Abstract
Rackground: As the transm Eaton Building, 10th Floor
200 Elizabeth Street, Toro
E-mail: aysegul.erman@m
Abstract
Background: As the transi

Abstract

200 Elizabeth Street, Toron
E-mail: aysegul.erman@ma
**Abstract
Background:** As the transm
the already strained heal 2012 E-mail: aysegul.erman@mail.utoronto.ca
2012 E-mail: aysegul.erman@mail.utoronto.ca
2013 Abstract
2014 Background: As the transmission of SARS-C
2014 Heady strained health systems is beliterature on the effects of vari E-mail: aysegul.erman@mail.utoronto.ca
 Abstract
 Background: As the transmission of SARS-

the already strained health systems is

literature on the effects of various variar

which VOCs may lead to more severe dise
 /
| t |
| ^ |

Background: As the transmission of SARS-COV-2 variants intensifies globally, the burden of COVID-19 of the already strained health systems is becoming increasingly concerning. While there is growing literature on the effec literature on the effects of various variants-of-concern (VOC) on increased transmission, the extent to
which VOCs may lead to more severe disease remains debated.
Methods: In the current analysis, we use a population-base which VOCs may lead to more severe disease remains debated.

Methods: In the current analysis, we use a population-based propensity-score matched cohort study of

all incident laboratory-confirmed COVID-19 cases with VOC t Methods: In the current analysis, we use a population-based p
all incident laboratory-confirmed COVID-19 cases with VOC
healthcare resource use and health outcomes attributable to
January 1 and April 9, 2021, relative to t

Methods: In the carlent analysis, we use a population-based propensity score inatented cohort study of
all incident laboratory-confirmed COVID-19 cases with VOC testing in Ontario, Canada to estimate
healthcare resource us healthcare resource use and health outcomes attributable to VOCs introduced to Ontario between
January 1 and April 9, 2021, relative to the previously circulating wild-type strain.
Results: We find that VOCs are associat January 1 and April 9, 2021, relative to the previously circulating wild-type strain.
 Results: We find that VOCs are associated with a higher odds of hospitalisation (odds ratio [OR], 2.25;

95% confidence interval [CI] Results: We find that VOCs are associated with a higher odds of hospitalisation 95% confidence interval [Cl], 2.10-2.40) and ICU admission (OR, 3.31; 95%Cl, 2.84 higher odds of mortality for both the general COVID-19 popul Results: We find that VOCs are associated with a higher odds of hospitalisation (odds ratio [OR], 2.25;
95% confidence interval [Cl], 2.10-2.40) and ICU admission (OR, 3.31; 95%Cl, 2.84-3.86); as well as with a
higher odds higher odds of mortality for both the general COVID-19 population (OR 1.75; 1.47-2.09) and hospitalised
cases (OR, 1.62; 95%Cl, 1.23-2.15).
Conclusion: Taken together, these findings suggest that health systems may face

Conclusion: Taken together, these
healthcare resources as VOCs predent
Acknowledgments: We thank Huitidata collection.

cases (OR, 1.62; 95%Cl, 1.23-2.15).
 Conclusion: Taken together, these findings suggest that health systems may face increased demand for

healthcare resources as VOCs predominate worldwide in view of low global vaccinat Conclusion: Taken together, these midings suggest that health systems may face increased demand for
healthcare resources as VOCs predominate worldwide in view of low global vaccination coverage.
Acknowledgments: We thank H healthcare resources as $V = 2$ predominate worldwide in view of low global vacantion resources as Acknowledgments: We thank Huiting Ma, MSc (Unity Health Toronto, Toronto Canada) for suppodata collection.
Adata collection. Acknowledgments: We thank Huiting Ma, MSc (Unity Health Toronto, Toronto Canada) for support with
data collection.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used

The rapid spread of COVID-19 variants-of-concern (VOC) continues to be a global challenge.⁴ As VOC
transmission intensifies the growing burden of COVID-19 on the already strained health systems remai
a worldwide problem. a worldwide problem. Although there is growing literature on the effects of various VOC strains on
increased transmission, the extent to which variants may lead to more severe disease remains
debated.¹⁻⁷ While, large st increased transmission, the extent to which variants may lead to more severe disease remains debated.¹⁻⁷ While, large studies involving community-based samples have shown associations between the B.1.1.7 and mortality, debated.¹⁻⁷ While, large studies involving community-based samples have shown associations k
the B.1.1.7 and mortality, a hospital based study found no differences in terms of disease sever
B.1.1.7 vs. non-B.1.1.7 strain debated.² ' While, large studies involving community-based samples have shown associations between
the B.1.1.7 and mortality, a hospital based study found no differences in terms of disease severity for
B.1.1.7 vs. non-B B.1.1.7 vs. non-B.1.1.7 strains following adjustment for age, sex, ethnicity, and comorbidities.¹⁻⁶
Differences with respect to study population, possible selection bias in communities-based samples w
non-routine VOC te B.1.1.7 vs. non-B.1.1.7 strains following adjustment for age, sex, ethnicity, and comorbidities.²
Differences with respect to study population, possible selection bias in communities-based samp
non-routine VOC testing ha non-routine VOC testing have been proposed to explain these contradictory findings.⁴ Thus, it remains
unclear the level to which B.1.1.7, which has now become the predominant variant in many regions can
contribute to dis non-routine VOC testing have been proposed to explain these contradictory findings.

unclear the level to which B.1.1.7, which has now become the predominant variant in

contribute to disease severity relative to the strai Thus, it remains
many regions car
es of the
rtality has largely
tcomes
ly circulating wild
dent laboratory-
where routine VO

contribute to disease severity relative to the strains that predominated in earlier phases of the
pandemic.⁴ Moreover, the effects of VOC on indicators of disease severity beyond mortality has largely
been overlooked in pandemic.⁴ Moreover, the effects of VOC on indicators of disease severity beyond mortality has
been overlooked in the existing literature.
In the current analysis we present estimates of healthcare resource use and healt pandemic."
been overlo
In the curre
attributable
type strains
confirmed (
testing was
estimate ho boked in the existing literature.

Interantives of healthcare resource use and health outcomes

Let o VOCs that harbour N501Y and/or E484K mutations relative to previously circulating wild

Is using population-based propen In the current analysis we present estimate
attributable to VOCs that harbour N501Y a
type strains using population-based proper
confirmed COVID-19 cases with VOC testin
testing was available for all positive sample
estima attributable to VOCs that harbour N501Y and/or E484K mutations relative to previously circulaty
type strains using population-based propensity-score matched cohort study of all incident labe
confirmed COVID-19 cases with V testing was available for all positive samples starting February 3, 2021. Our primary objective was to
estimate hospitalisation and deaths attributable to VOC compared with prior strains among the general
population (cohor testimate hospitalisation and deaths attributable to VOC compared with prior strains among the general population (cohort 1); our secondary objective was to estimate VOC-attributable deaths and time-to-
hospitalisation amo estimate the principal attributable to the strains attributable deaths and time-to-
hospitalisation among hospitalised cases of COVID-19 (cohort 2).
Methods
Study setting and design
A population-based propensity-score ma

attributable to V and \mathcal{S} and \mathcal{S} and or E484K mutations relative to previously circulating wild-or E484K mutations relative to \mathcal{S} and \mathcal{S} and \mathcal{S} and \mathcal{S} arboring wild-order wild-order wi

Study setting and design

19 cases with VOC testing in Ontario during the period from January 1, 2021 to April 9, 2021 was
conducted. Subjects included in the matched cohort were followed up to April 19, 2021 to estimate Methods
Study setting and design
A population-based propensity-score matched cohort study of all
19 cases with VOC testing in Ontario during the period from Januar
conducted. Subjects included in the matched cohort were fo

Data sources:

and report it to the Ministry of Health and Long-Term Care for surveillance purposes. This dataset 19 conducted. Subjects included in the matched cohort were followed up to April 19, 2021 to estima
19 vOC-attributable risk of hospitalization, ICU admission and mortality.
19 **Data sources:**
19 ve used Case and Contact Ma VOC-attributable risk of hospitalization, ICU admission and mortality.
 Data sources:

We used Case and Contact Management System (CCM) data, which is the central repository used by

public health units in Ontario to col Vocalization of the problems of the problems and mortality.

Data sources:

We used Case and Contact Management System (CCM) data, which is

public health units in Ontario to collect information on individuals wit

and rep public health units in Ontario to collect information on individuals with COVID-19 in their jurisdiction
and report it to the Ministry of Health and Long-Term Care for surveillance purposes. This dataset
contains data on a public and report it to the Ministry of Health and Long-Term Care for surveillance purposes. This dataset
contains data on all reported cases of COVID-19 in Ontario, Canada's largest jurisdiction (population 1
million). Th and reportains data on all reported cases of COVID-19 in Ontario, Canada's largest jurisdiction (population). The CCM dataset was used to collect information on all individuals who test positive for SCOV-2 in Ontario inclu million). The CCM dataset was used to collect information on all individuals who test positive for SARS-CoV-2 in Ontario including VOC status, long-term care residency, age, sex, comorbidities, geography, demographics, dat Cover and children including VOC status, long-contract residency, and children including y google-properties,
demographics, dates of testing, dates of hospital admission and health outcomes (i.e. death,
hospitalisation, IC μ_{data} , dates of testing, dates of hospitalisation, μ_{data} , hospitalisation, μ_{data} , $\mu_{$ hospitalisation, ICU admission, intubation or ventilation). \sim

Study subjects

routine VOC testing status on record (i.e., VOC-detected, vs. not detected).⁸ In Ontario, all positive samples are routinely screened for N501Y single target test starting February 3, 2021 and all PCR-positive specimens routine VOC testing status on record (i.e., VOC-detected, vs. not detected)."
samples are routinely screened for N501Y single target test starting Februar
positive specimens with Ct value ≤35 are tested for the N501Y and E y 3, 2021 and all PCR-
utations with multiplex
are homes and cases wi
tection. In general, VO
[U.K variant 202012/01
01Y.V3]). In total we
eligibility and were inclu
212 subjects who had a hospital admission and a valid admission date (cohort 2). missing covariate data. The index date was chosen as date of SARS-CoV-2 detection. In general, VOCs
included variants that harbour N501Y and/or E484K mutations (e.g., B.1.1.7 [U.K variant 202012/01], l
[Brazil variant], B. included variants that harbour N501Y and/or E484K mutations (e.g., B.1.1.7 [U.K variant 202012/01], [Brazil variant], B.1.351 [South African variant 501Y.V2], P.1 [Brazil variant 501Y.V3]). In total we identified 77,200 su included variant], B.1.351 [South African variant 501Y.V2], P.1 [Brazil variant 501Y.V3]). In total we
[Brazil variant], B.1.351 [South African variant 501Y.V2], P.1 [Brazil variant 501Y.V3]). In total we
identified 77,200 identified 77,200 subjects with a confirmed SARS-CoV-2 infection that met eligibility and were ine
in the primary analysis (cohort 1). In the secondary analysis we identified 2,212 subjects who had
hospital admission and a

\blacksquare Matched cohort analysis

in the primary analysis (cohort 1). In the secondary analysis we identified 2,212 subjects who had a
hospital admission and a valid admission date (cohort 2).
Matched cohort analysis
In the primary analysis (cohort 1), a in the primary analysis

in the primary analysis

in the primary analysis (cohort 1), a matched cohort analysis was conducted to estimate the VOC

attributable odds of hospitalisation, ICU admission, and death among all in Matched cohort analysis

In the primary analysis (cohort 1), a matched cohort analy

attributable odds of hospitalisation, ICU admission, and d

COIVD-19 population. We matched each exposed individu

(no VOC-detected) indi attributable odds of hospitalisation, ICU admission, and death among all infected subjects in the g
COIVD-19 population. We matched each exposed individual (VOC-detected) to up to three unexpe
(no VOC-detected) individuals COIVD-19 population. We matched each exposed individual (VOC-detected) to up to three unexposed
(no VOC-detected) individuals using nearest neighbour matching with replacement. Subjects were
matched using a combination of (no VOC-detected) individuals using nearest neighbour matching with replacement. Subjects were matched using a combination of hard matching (for age group, sex and income quintile) and propensits
score matching using a ca (noting a combination of hard matching (for age group, sex and income quintile) and prope
score matching using a caliper width equal to 0.25 of the standard deviation of the logit of the
propensity score.¹⁰ Covariates i score matching using a caliper width equal to 0.25 of the standard deviation of the logit of the
propensity score.¹⁰ Covariates included in the propensity score included the week of detection, age, sex,
rurality, income propensity score.¹⁰ Covariates included in the propensity score included the week of detection
rurality, income quintile, and presence of three or more comorbidities on record (including ren
condition, immunocompromised, propensity score.²⁰ Covariates included in the propensity score included the week of detection, age, sex, rurality, income quintile, and presence of three or more comorbidities on record (including renal condition, immun

condition, immunocompromised, chronic obstructive pulmonary disease, obesity, diabetes, cance
cardiovascular disease, injection drug use, neurologic disorders and chronic liver disease).^{8,9} The
characteristics of study s cardiovascular disease, injection drug use, neurologic disorders and chronic liver disease).^{8,9} The
characteristics of study subjects included in cohort 1 are displayed in **Table 1**.
In a secondary analysis (cohort 2), a cardiovascular disease, injection drug use, neurologic disorders and chronic liver disease).^{9,97} The characteristics of study subjects included in cohort 1 are displayed in **Table 1**.
In a secondary analysis (cohort 2), characteristics of study subjects included in cohort 1 are displayed in Table 1.
In a secondary analysis (cohort 2), a matched cohort analysis was undertaken
attributable time-to-hospital admission and odds of death, ICU a In a stributable time-to-hospital admission and odds of death, ICU admission and ventilation/intubatics specifically among hospitalised COVID-19 subjects. We matched hospitalized subjects with VOC exposure to hospitalized specifically among hospitalised COVID-19 subjects. We matched hospitalized subjects with VOC
exposure to hospitalized non-VOC exposed subjects using the same matching approach as in cohort 1
The characteristics of study su

Supplementary analysis

specifically among the principle among the product of the characteristics of study subjects included in cohort 2 are displayed in **Table 2**.
The characteristics of study subjects included in cohort 2 are displayed in **Tabl** The characteristics of study subjects included in cohort 2 are displayed in **Table 2**.
Supplementary analysis
Because data on ICU-related outcomes is likely to be underreported in the CCM dataset by ~45% at the
time of the The characteristics of study subjects included in cohort 2 are displayed in Table 2.
 Supplementary analysis

Because data on ICU-related outcomes is likely to be underreported in the CCM da

time of the analysis, these

Sensitivity analysis

time of the analysis, these ICU-related outcomes (i.e., ICU admission and ventilation/intubation) were
only included as a supplemental analysis and should be interpreted with caution.
Sensitivity analysis
To account for the analysis and should be interpreted with caution.
Sensitivity analysis
To account for the effects of right censoring, in a sensitivity analysis both cohorts were further restrict
to patients who had an outcome on record **Sensitivity analysis**
To account for the effects of right censoring, in a sensitivity analysis both cohorts
to patients who had an outcome on record with respect to their infection status (
fatal). In the restricted anal to patients who had an outcome on record with respect to their infection status (i.e., recovered, or fatal). In the restricted analysis, optimal full matching with a caliper restriction was chosen to use all available data to particular who had an outcome on record with respect to the infection was chosen to use all available data in this subset.¹²
available data in this subset.¹²
2 factor). In the restricted analysis, optimal function was chosen to use all matching with a calibration was chosen to use $2²$ available data in this subset.12

Statistical analysis

 For all matched sets, the matched individuals. For binary outcomes, attributable
SD<0.1 indicating negligible differences between matched individuals. For binary outcomes, attributable
outcomes were estimated using conditi outcomes were estimated using conditional logistic regression.¹³ Statistical analyses were performed
using R version 3.6.3 with RStudio (R Core Team, 2020). "Matchlt" package was used to match subjects.
Results
In the

Matched cohort analysis of all COVID-19 infections

outcomes were estimated using conditional logistic regression.²⁵ Statistical analyses were performed
using R version 3.6.3 with RStudio (R Core Team, 2020). "Matchlt" package was used to match subject
Results
In the pr Results

Matched cohort analysis of all COVID-19 infections

In the primary analysis (cohort 1), a matched cohort analysis was conducted to estimate the VOC

attributable odds of hospitalisation, ICU admission and death am attributable odds of hospitalisation, ICU admission and death among all infected subjects in the grad COVID-19 population. In total, we identified 27,743 non-VOC and 49,457 VOC-infected subjects the ligibility. On average, COVID-19 population. In total, we identified 27,743 non-VOC and 49,457 VOC-infected subjects that met
eligibility. On average, VOC-infected individuals tended to be slightly younger (37 vs. 38 years), more
likely to reside

eligibility. On average, VOC-infected individuals tended to be slightly younger (37 vs. 38 years), more likely to reside in a large urban center (86 % vs. 76%), and more likely to be infected at a later time when compared likely to reside in a large urban center (86 % vs. 76%), and more likely to be infected at a later time wl
compared to subjects infected with a non-VOC strain (**Table 1**).
We matched each exposed individual (VOC-detected) compared to subjects infected with a non-VOC strain (**Table 1**).
We matched each exposed individual (VOC-detected) to up to three unexposed (no VOC-detected)
individuals using nearest neighbour matching with replacement) t compared to subjects infected with a non-VOC strain (Table 1).
We matched each exposed individual (VOC-detected) to up to tl
individuals using nearest neighbour matching with replacement
whereby standardised differences we individuals using nearest neighbour matching with replacement) to achieve a balanced matches
whereby standardised differences were less than 10% for all covariates. We were able to match all
infected individuals (N=49,457 whereby standardised differences were less than 10% for all covariates. We were able to match
infected individuals (N=49,457) to non-VOC individuals (N=13,413). The matched cohort had an a
age of 37 years, 51% were male,

(Table 3). When we stratified results by age and sex, the impact of VOC on outcomes were consistent age of 37 years, 51% were male, and less than 1% of subjects had 3 or more comorbid conditions. A
large majority (87%) of matched subjects resided in a large urban population center, with only 2%
residing in rural areas (age majority (87%) of matched subjects resided in a large urban population center, with only 2%
residing in rural areas (**Table 1**).
In the matched analysis for cohort 1, we found VOC exposure was associated with 2.25 (95% large majority (1999) of matching parametering mannippediately, matching in the matched analysis for cohort 1, we found VOC exposure was associated with 2.25 (95%Cl, 2.
2.40) times higher odds of hospitalisation 3.31 (95%C residing in rural areas (Table 1).

In the matched analysis for cohe

2.40) times higher odds of hospi

and 1.75 (95%Cl, 1.74-22.09) tim

(Table 3). When we stratified res

across age and sex strata. In fact

and ICU admis 2.40) times higher odds of hospitalisation 3.31 (95%Cl, 2.17-3.95) times higher odds of ICU admission
and 1.75 (95%Cl, 1.74-22.09) times higher odds of death compared to non-VOC-exposed individuals
(**Table 3**). When we str and 1.75 (95%Cl, 1.74-22.09) times higher odds of death compared to non-VOC-exposed individuals (Table 3). When we stratified results by age and sex, the impact of VOC on outcomes were consistent across age and sex strata. (Table 3). When we stratified results by age and sex, the impact of VOC on outcomes were consisten
across age and sex strata. In fact, VOC exposure led to a larger increase in the odds of hospitalisatior
and ICU admission (Table 3). When we stratified results by age and sex, the impact of VOC on outcomes were consistent
across age and sex strata. In fact, VOC exposure led to a larger increase in the odds of hospitalisation
and ICU admission and ICU admission among male subjects relative to females (**Table 4**). In general we also found a trentowards greater healthcare resource use (i.e., hospital and ICU admission) for younger individuals wit VOC-exposure rela and Ico damission among male subjects relative to females (Table 4). In general we diso found a trend
towards greater healthcare resource use (i.e., hospital and ICU admission) for younger individuals with
VOC-exposure rel

VOC-exposure relative older patients (Table 4); albeit ongoing vaccine roll out targeting older subjects
during the study timeframe may have some impact owing to possible differences in vaccine
effectiveness with respect t voce-exposure relative older patients (Table 4), about ongoing vaccine roll out targeting older subjects
during the study timeframe may have some impact owing to possible differences in vaccine
effectiveness with respect t effectiveness with respect to VOC and wild-type strains.
In a sensitivity analysis we further restricted the analysis to patients who had a reported out
record (i.e., recovered, or fatal). We were able to match 99% of VOC-In a sensitivity analysis we further restricted the analysis
record (i.e., recovered, or fatal). We were able to match
non-VOC individuals (N=14,242). The characteristics of st
cohort 1 are displayed in **Supplemental Tabl** Frecord (i.e., recovered, or fatal). We were able to match 99% of VOC-infected individuals (N=17,742) tonn-VOC individuals (N=14,242). The characteristics of study subjects included the sensitivity analysis cohort 1 are d non-VOC individuals (N=14,242). The characteristics of study subjects included the sensitivity analysis fc
cohort 1 are displayed in **Supplemental Table 1**. The average age of the matched cohort was 35 years,
52% were male non-Vocality in Supplemental Table 1. The average age of the matched cohort was 35 years,
52% were male. A large majority ~76% of matched subjects resided in large urban areas. Compared to
the main analysis, individuals in cohort I are displayed in Supplemental Table 1. The average age of the matched cohort was 35 years,
52% were male. A large majority ~76% of matched subjects resided in large urban areas. Compared to
the main analysis, indi the main analysis, individuals included in the sensitivity analysis experienced more frequent
hospitalisation, ICU admissions and death. This is likely due to both the removal of censored data and
3 the main analysis in the main and death. This is likely due to both the removal of censored more frequently contained by the sensitivity of the sensored more frequently contained by the sensitivity of the sensored more fre hospitalisation, ICU admissions and death. This is likely due to both the removal of censored data and

with a documented outcome owing to the closer monitoring of more severe cases. Nonetheless, the
results of the sensitivity analysis for cohort 1 were highly congruent with the main analysis. In the
sensitivity analysis, we results of the sensitivity analysis for cohort 1 were highly congruent with the main analysis. In the
sensitivity analysis, we found a 1.95 (95% Cl, 1.69-2.25) times higher odds of hospitalisation, 2.43
(95%Cl, 1.78-3.32) sensitivity analysis, we found a 1.95 (95% Cl, 1.69-2.25) times higher odds of hospitalisation , 2.43
(95%Cl, 1.78-3.32) times higher odds of ICU admission, and 1.91 (95%Cl, 1.35-2.38) times higher o
death among those expo

Matched cohort analysis of hospitalised cases of COVID-19

sensitivity analysis, the bigger odds of ICU admission, and 1.91 (95%CI, 1.35-2.38) times higher of
death among those exposed to a VOC strain (Table 3).
Matched cohort analysis of hospitalised cases of COVID-19
To assess t (51%CI) death among those exposed to a VOC strain (Table 3).

Matched cohort analysis of hospitalised cases of COVID-19

To assess the VOC-attributable outcomes specifically among hospitalised subjects, in a secondary

ana Matched cohort analysis of hospitalised cases of COV
To assess the VOC-attributable outcomes specifically a
analysis (cohort 2), we performed a matched cohort ar
patients. In total, we identified 582 non-VOC and 1,630
admi analysis (cohort 2), we performed a matched cohort analysis in this population of hospitalised CO
patients. In total, we identified 582 non-VOC and 1,630 VOC-infected subjects with a valid hospita
admission on record. In g analysis (controllar), we performed a matched a matched controllar performed a material controllar admission on record. In general, when compared to the general COVID-19 population, hospitalised subjects were older (62 vs particulary and the general, when compared to the general COVID-19 population, hospitalised
subjects were older (62 vs 37) and were more likely to belong to the two lowest income quintiles (5
vs 46 %). In the hospitalised subjects were older (62 vs 37) and were more likely to belong to the two lowest income quintiles (5
vs 46 %). In the hospitalised cohort, relative to subjects admitted to hospitalised with a non-VOC
infection, those hospit subjects were obtained to hospitalised with a non-VOC
infection, those hospitalised cohort, relative to subjects admitted to hospitalised with a non-VOC
infection, those hospitalised with a VOC infection were younger (59 v

infection, those hospitalised with a VOC infection were younger (59 vs. 64 years), had less
comorbidities, were more likely to be male (57% vs. 52%) and more likely to reside in large urban
population centers (84% vs 72%), comorbidities, were more likely to be male (57% vs. 52%) and more likely to reside in large
population centers (84% vs 72%), and were also infected later (**Table 2**).
For hospitalised subjects (cohort 2), we were able to m population centers (84% vs 72%), and were also infected later (**Table 2**).
For hospitalised subjects (cohort 2), we were able to match 77% VOC-infected individuals (N=1,24
non-VOC individuals (N=418) using the same matchin population centers (84% vs 72%), and were also infected later (Table 2).
For hospitalised subjects (cohort 2), we were able to match 77% VOC-inf
non-VOC individuals (N=418) using the same matching approach as in co
match f non-VOC individuals (N=418) using the same matching approach as in cohort 1 to achieve a balanced
match for all covariates (**Table 2**). The average age of the matched cohort was 62 years, 60% were male
a large majority (84

match for all covariates (**Table 2**). The average age of the matched cohort was 62 years, 60% were matched for all covariates (**Table 2**). The average age of the matched cohort was 62 years, 60% were material already appro match for all covariates (Table 2). The average age of the matched cohort was 62 years, 60% were male,
a large majority (84%) of matched subjects resided in a large urban area. Finally, most subjects in the
hospitalised co hospitalised cohort (56%) belonged to the two lowest income quintiles.
In the matched analysis for cohort 2, we found that on average, VOC-exposed subjects took 0.61 days
(95%Cl 0.34-0.87) longer from detection of infectio In the matched analysis for cohort 2, we found that on average, VOC-exp
(95%Cl 0.34-0.87) longer from detection of infection to hospital admission
infected with a non-VOC strain (Table 3). Among hospitalised subjects, t
2. (95%Cl 0.34-0.87) longer from detection of infection to hospital admission compared to individuals
infected with a non-VOC strain (**Table 3**). Among hospitalised subjects, the odds of ICU admission was
2.56 (95%Cl, 2.10-3. infected with a non-VOC strain (**Table 3**). Among hospitalised subjects, the odds of ICU admission w
2.56 (95%Cl, 2.10-3.13) times higher, and death was 1.62 (95%Cl, 1.23-2.15) times higher with VOC-
exposure relative to e

infected with a non-VOC strain (Table 3). Among hospitalised subjects, the odds of ICO dumission was
2.56 (95%Cl, 2.10-3.13) times higher, and death was 1.62 (95%Cl, 1.23-2.15) times higher with VOC-
exposure relative to e (Supplemental Table 2). The average age of the matched cohort was 65 years, 55% were male, ~80%
resided in a large urban population center. When compared to the main analysis on hospitalised exposition between VOC exposure and ventilation/intubation in this population (Table 3).

When we further restricted the analysis of hospitalised patients to subjects with a reported outcome

record (i.e., recovered, or fa association between VOC exposure and ventilation/intubation in this population (Table 3).
When we further restricted the analysis of hospitalised patients to subjects with a reported
record (i.e., recovered, or fatal) in t record (i.e., recovered, or fatal) in the sensitivity analysis, we identified 326 non-VOC and 580 VOC-
exposed subjects, and were able to match 61% VOC-infected individuals with a hospital admission
(N=351) to non-VOC indi 1.02-2.59) and ICU admission (OR, 2.31; 95%CI, 1.31-4.06); however, time-to-hospital admission was not
found to be significantly longer for VOC-exposed subjects in the sensitivity analysis (Table 3). In (N=351) to non-VOC individuals (N=240) using optimal full matching to achieve balanced matches
(Supplemental Table 2). The average age of the matched cohort was 65 years, 55% were male, ~80
resided in a large urban popula (Supplemental Table 2). The average age of the matched cohort was 65 years, 55% were male, ~8
resided in a large urban population center. When compared to the main analysis on hospitalised
individuals, individuals included (Suppremental Table 2). The average age of the matched conort was 65 years, 55% were male, ~60% resided in a large urban population center. When compared to the main analysis on hospitalised individuals, individuals includ individuals, individuals included in the sensitivity analysis had substantially higher mortality but n
more frequent ICU admission or ventilation/intubation. Once again, consistent with the main ana
the sensitivity analysi more frequent ICU admission or ventilation/intubation. Once again, consistent with the main analys
the sensitivity analysis, VOC-exposure retained a significant association with mortality (OR, 1.63; (95
1.02-2.59) and ICU the sensitivity analysis, VOC-exposure retained a significant association with mortality (OR, 1.63; (95%Cl, 1.02-2.59) and ICU admission (OR, 2.31; 95%Cl, 1.31-4.06); however, time-to-hospital admission was not found to be 1.02-2.59) and ICU admission (OR, 2.31; 95%Cl, 1.31-4.06); however, time-to-hospital admission was not
found to be significantly longer for VOC-exposed subjects in the sensitivity analysis (**Table 3**). In
accordance with t 1.02-2.59) and ICU admission (OR, 2.31; 95%CI, 1.31-4.06); however, time-to-hospital admission was not found to be significantly longer for VOC-exposed subjects in the sensitivity analysis (Table 3). In
accordance with the main analyse, we also did not find a statistically significant association betw
VOC exposure and venti accordance with the main analyse, we are can be characterized a statistically significant association between $(Table 3)$. VOC exposure and ventilation/intubation (Table 3).

In boratory-confirmed COVID-19 cases with VOC testing in Ontario between January, 1, 2021 and April
2021 to estimate the healthcare recourse use and health outcomes attributable to VOC compared wit
previously circulating s national confirmed COVID-19 confirmed COVID-19 cases with the healthcare recourse use and health outcomes attributable to VOC compared with previously circulating strains in Ontario.
In summary, this study demonstrates tha previously circulating strains in Ontario.

In summary, this study demonstrates that relative to earlier wild-type strains, VOCs that have been

introduced to Ontario during the study timeframe have resulted in higher mort In summary, this study demonstrates that
introduced to Ontario during the study t
COVID-19 population and for hospitalise
previous studies that have also demonst
lineage.^{1,2,5} However, in contrast to a pre
are associated introduced to Ontario during the study timeframe have resulted in higher mortality for both the ger
COVID-19 population and for hospitalised cases of COVID-19. These findings are largely congruent w
previous studies that h COVID-19 population and for hospitalised cases of COVID-19. These findings are largely congruent with
previous studies that have also demonstrated an increase in mortality associated with the B.1.1.7
lineage.^{1,2,5} Howeve previous studies that have also demonstrated an increase in mortality associated with the B.1.1.7
lineage.^{1,2,5} However, in contrast to a previous study involving hospitalised subjects, we find that VOCs
are associated w lineage.^{1,2,5} However, in contrast to a previous study involving hospitalised subjects, we find that V
are associated with increased mortality among hospitalised individuals. Moreover, while earlier
investigations have n lineage.^{2,2,2},² However, in contrast to a previous study involving hospitalised subjects, we find that VOCs
are associated with increased mortality among hospitalised individuals. Moreover, while earlier
investigations investigations have not assessed other important metrics of disease severity, in the current studes found that compared to previously circulating strains, VOC-strains predominant in Ontario at time of analysis were also as investigation and a subset of bosoidalised subjects. Our study is trengthened by the application and a subset of bosoidalised subjects. Our study is trengthened by the application, these findings were not found to be sensi time of analysis were also associated with higher healthcare resource use (e.g., hospital and ICU
admission); as well as a longer time-to hospital admission. Apart from time-to-hospitalisation, these
findings were not foun

admission); as well as a longer time-to hospital admission. Apart from time-to-hospitalisation, th
findings were not found to be sensitive to the exclusion of individuals with incomplete data on th
outcome of the infection Findings were not found to be sensitive to the exclusion of individuals with incomplete data on the outcome of the infection.

Our analysis contributes to the current literature by using a large population-based sample of outcome of the infection.
Our analysis contributes to the current literature by using a large population-based sample of all CC
19 cases identified in Ontario with routine VOC testing and by including an analysis of both t Our analysis contributes to
19 cases identified in Onta
COVID-19 population and
of a propensity-score mat
(i.e., age, sex, socioeconor
bias. Moreover, the availa
VOC testing reduce selection Our analysis contribution to the current literature by using a large population-based sample of all COVID-DV α COVID-19 population and a subset of hospitalised subjects. Our study is strengthened by the application
of a propensity-score matched cohort study design, the ability to account for important confounders
(i.e., age, sex, s of a propensity-score matched cohort study design, the ability to account for important confounders
(i.e., age, sex, socioeconomic status, comorbidities, geography, and time-of-detection), hence reducing
bias. Moreover, th (i.e., age, sex, socioeconomic status, comorbidities, geography, and time-of-detection), hence reducir
bias. Moreover, the availability of a large population-based sample of all COVID-19 cases with routine
VOC testing redu bias. Moreover, the availability of a large population-based sample of all COVID-19 cases with routine
VOC testing reduce selection bias and increase generalizability of study findings. Finally, we also explore
indicators

VOC testing reduce selection bias and increase generalizability of study findings. Finally, we also exploindicators of disease severity beyond mortality such as hospital admission, ICU admission and ventilation/intubation VOC testing reduce selective produce in the matter of the analysis in the inability to control for unmeasure

However, our study also has limitations. The analysis is limited by the inability to control for unmeasure

conf indication/intubation.

However, our study also has limitations. The analysis is limited by the inability to control for unconfounders especially in terms of missing comorbidity profiles and by right censoring of data.

al Framman, manutation.
However, our study also
confounders especially
also unable to stratify b
majority VOC cases are
to be underreported in
ICU admission and vent
In conclusion, this study For the andent sespecially in terms of missing comorbidity profiles and by right censoring of data. We were also unable to stratify by specific VOC lineage given lagging sequencing information, though the vast majority VOC also unable to stratify by specific VOC lineage given lagging sequencing information, though the vast
majority VOC cases are likely to be B.1.1.7.¹¹ Moreover, because data on ICU-related outcomes is likely
to be underre

majority VOC cases are likely to be B.1.1.7.¹¹ Moreover, because data on ICU-related outcomes is like
to be underreported in the CCM dataset by ~45% at the time of the analysis, ICU-related outcomes (i
ICU admission and majority VOC cases are likely to be B.1.1.7. ²² Moreover, because data on ICU-related outcomes is likely
to be underreported in the CCM dataset by ~45% at the time of the analysis, ICU-related outcomes (i.e.,
ICU admissi ICU admission and ventilation/intubation) should be interpreted with caution.
In conclusion, this study suggests that VOCs that that harbour the N501Y mutation, which confers
greater infectivity, is also associated with mo In conclusion, this study suggests that VOCs that that harbour the N501Y muta
greater infectivity, is also associated with more severe disease manifestations if
Taken together, these findings suggest that compared to the p In the study is also associated with more severe disease manifestations relative to earlier straken together, these findings suggest that compared to the previous phases of the pandemic, heaven will likely face increased d Greater infective infective manifology and the previous phases of the pandemic, health systems will likely face increased demand for acute care hospital and ICU resources as VOCs predominate worldwide, especially in view o systems will likely face increased demand for acute care hospital and ICU resources as VOCs
predominate worldwide, especially in view of limited global vaccination coverage. Therefore, prompt
vaccine roll-out particularly system water world and the precision of the system of the demand of the control of the preformation of the proton matricularly in regions with high incidence of VOC is warranted to reduce the burden of COVID-19 going forwa predominate roll-out particularly in regions with high incidence of VOC is warranted to reduce the global burden of COVID-19 going forward.

burden of COVID-19 going forward.

5 burden of COVID-19 going forward.

5 burden of COVID-19 going forward.

References:

- $\mathbf{1}$.
-
- lineage B.1.1.7 in England. *Science*. Published online 2021. doi:10.1126/science.abg3055

2. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortal

patients infected with SARS-CoV-2 v Inteage B.1.1.7 in England. Science. Plassified online 2021. doi.10.1120/science.abg3033
Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mo
patients infected with SARS-CoV-2 variant of patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ.*

2021;372:n579. doi:10.1136/bmj.n579

3. Patone M, Thomas K, Hatch R, et al. Analysis of severe outcomes associated with the SARSpatients infected with SARS-Cov-2 variant of concern 202012/1: matched conort study: BMJ.
2021;372:n579. doi:10.1136/bmj.n579
Patone M, Thomas K, Hatch R, et al. Analysis of severe outcomes associated with the SARS-Co
Vari Patone M, Thomas K, Hatch R, et al. An
Variant of Concern 202012/01 in Englar
databases. *medRxiv*. Published online Ja
doi:10.1101/2021.03.11.21253364
Ong SWX, Young BE, Lye DC. Lack of dei
2 variants of concern and clini Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch
databases. *medRxiv*. Published online January 1, 2021:2021.03.11.21253364.
doi:10.1101/2021.03.11.21253364
4. Ong SWX, Young BE, Lye DC
- databases. *medRxiv.* Published online January 1, 2021:2021.03.11.21253364.
doi:10.1101/2021.03.11.21253364
Ong SWX, Young BE, Lye DC. Lack of detail in population-level data impedes analysis of SARS-
2 variants of concern doi:10.1101/2021.03.11.21253364
doi:10.1101/2021.03.11.21253364
Ong SWX, Young BE, Lye DC. Lack of detail in population-level data impedes a
2 variants of concern and clinical outcomes. *Lancet Infect Dis.* Published onlin Ong SWX, Young BE, Lye DC. Lack of
2 variants of concern and clinical ou
doi:10.1016/S1473-3099(21)00201
Grint DJ, Wing K, Williamson E, et a
B.1.1.7 in England, 16 November to
doi:https://doi.org/10.2807/1560-7
Frampton D
-
- emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-
based cohort study. *Lancet Infect Dis.* Published online May 11, 2021. doi:10.1016/S1473-2 variants of concern and clinical outcomes. *Lancet inject Dis.* Published online April 2021.

doi:10.1016/S1473-3099(21)00201-2

Grint DJ, Wing K, Williamson E, et al. Case fatality risk of the SARS-CoV-2 variant of conc Grint DJ, Wing K, Williamson E, et al. (B.1.1.7 in England, 16 November to 5
doi:https://doi.org/10.2807/1560-791
Frampton D, Rampling T, Cross A, et a
emergent SARS-CoV-2 B.1.1.7 lineage
based cohort study. *Lancet Infect* 5. B.1.1.7 in England, 16 November to 5 February. *Eurosurveillance*. 2021;26(11).

doi:https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256

Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical B.1.1.7 in England, 16 November to 5 February. Eurosurveillance. 2021,20(11).
doi:https://doi.org/10.2807/1560-7917.ES.2021.26.11.2100256
Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effe
em Frampton D, Rampling T, Cross A, et al. Genomic characteristics and the present SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-ge based cohort study. *Lancet Infect Dis.* Published online May 11, 3099(21)00170-5
Jewell emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hold based cohort study. *Lancet Infect Dis.* Published online May 11, 2021. doi:10.1016/S1473
3099(21)00170-5
7. Jewell BL. Monitoring diffe
-
-
- Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in Based cohort study. Lancet Infect Dis. Published online May 11, 2021. doi:10.1016/51473-3099(21)00170-5
Lewell BL. Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other linea
Lancet Public Heal. 2021;6(5) Exercises
Jewell BL. Monito
Lancet Public Hea:
iPHIS resources. P
www.publichealth
Austin PC. Optima
means and differe
doi:10.1002/pst.4 2. *Lancet Public Heal.* 2021;6(5):e267-e268. doi:10.1016/S2468-2667(21)00073-6

8. iPHIS resources. Public Health Ontario, Toronto. Accessed March 25, 2021.

www.publichealthontario.ca/en/diseases-and-conditions/infectiou EUTRET TUBE THEM. 2021,0(5):e207-e268. doi:10.1010/52408-2007(21)00073-0
iPHIS resources. Public Health Ontario, Toronto. Accessed March 25, 2021.
www.publichealthontario.ca/en/diseases-and-conditions/infectious-diseases/c www.publichealthontario.ca/en/diseases-and-conditions/infectious-disease

9. Austin PC. Optimal caliper widths for propensity-score matching when estir

means and differences in proportions in observational studies. *Pharm* Wartin PC. Optimal caliper widths for propensity-score matching when estimating differe
means and differences in proportions in observational studies. *Pharm Stat.* 2011;10(2):1
doi:10.1002/pst.433
Statistics Canada. Incom 9. Martin PC. Austin PC. Austin PC. Stuart EA. Estimating the effect of treatment on binary outcomes using full matching

10. Austin PC, Stuart EA. Estimating the effect of treatment on binary outcomes using full matching

-
-
- means and differences in proportions in observational studies. *Pharm Stat. 2011*;10(2):150-101.
doi:10.1002/pst.433
Statistics Canada. Income of Individuals.
https://www150.statcan.gc.ca/n1/en/catalogue/13C0015
Hansen BB, Statistics Canada. Inc
Statistics Canada. Inc
https://www150.stat
Hansen BB, Klopfer S
Graph Stat. 2006;15(
Austin PC, Stuart EA.
doi:10.1177/096228(https://www150.statcan.gc.ca/n1/en/ca
11. Hansen BB, Klopfer SO. Optimal Full Mat
6*raph Stat*. 2006;15(3):609-627. doi:10.1
12. Austin PC, Stuart EA. Estimating the effec
on the propensity score. Stat Methods M
doi:10.117 Hansen BB, Klopfer SO. Optimal Full Matching and Related
Graph Stat. 2006;15(3):609-627. doi:10.1198/106186006X
Austin PC, Stuart EA. Estimating the effect of treatment on
on the propensity score. Stat Methods Med Res. 201 11. Hansen BB, Kiepter 30. Optimal Full Matching and Related Designs via Network Flows. J comput

Graph Stat. 2006;15(3):609-627. doi:10.1198/106186006X137047

12. Austin PC, Stuart EA. Estimating the effect of treatment o Graph Stat. 2000,15(3):609-627. doi:10.1198710016000000000137047
Austin PC, Stuart EA. Estimating the effect of treatment on binary of
on the propensity score. *Stat Methods Med Res.* 2017;26(6):2505-3
doi:10.1177/09622802
- 11. Australian: The propensity score. Stat Methods Med Res. 2017;26(6):2505-2525.

doi:10.1177/0962280215601134

13. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Epidemiologic

Summary: COVID on the propensity score. Stat Methods Med Res. 2017;20(0):2505-2525.
doi:10.1177/0962280215601134
Ontario Agency for Health Protection and Promotion (Public Health Onta
Summary: COVID-19 in Ontario – January 15, 2020 to Ma Ontario Agency for Health Protect
Summary: COVID-19 in Ontario –
Printer for Ontario.; 2021.
. 13. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Epidemiologic
Summary: COVID-19 in Ontario – January 15, 2020 to March 26, 2021. Toronto, ON: Queen's
Printer for Ontario.; 2021. Summary: COVID-19 in Ontario – January 15, 2020 to March 26, 2021. Toronto, ON: Queen's
Printer for Ontario.; 2021. Printer for Ontario.; 2021.

Table 1: Characteristics of all infected subjects included in cohort 1

Table 1. Characteristic of all infected subjects (cohort 1). $^{\rm a}$ The cohort consist of all cases with a VOC status on record excluding long-term care residents. $^{\rm b}$ Proportion with 3 or more comorbidities. CVariant subtypes are non mutually exclusive. ^d Characteristics of VOC-exposed subjects excluded from the matched cohort analysis. Subjects were matched 1:3 with replacement using nearest neighbour matching using a combination of hard and propensity score matching with caliber of 0.25 of the standard deviation of the logit of the propensity score. *Bold indicates standardized differences >0.1. Abbreviations: VOC: Variant of concern; SD: standardized differences.

	Cohort prior to matching			Matched cohort			Unmatched subjects ^d
COHORT 2 [HOSPITALISED] ^a	Non-VOC	VOC	SD	Non-VOC	VOC	SD	VOC
	$N = 582$	$N = 1,630$		$N = 418$	$N = 1,249$		$N = 381$
Age in years (mean)	63.7	58.6	$0.32*$	62.2	62.3	0.01	46.5
Age groups (%)							
10	0.5	0.4	0.01	0.2	0.2	0.00	1.0
10-19	0.5	0.3	0.04	0.0	0.0	0.00	1.3
20 29	2.9	4.4	0.07	1.0	1.0	0.00	15.7
30 39	5.0	7.9	$0.11*$	2.5	2.5	0.00	25.7
40 49	9.3	14.8	$0.16*$	13.0	13.0	0.00	20.7
50 59	17.0	21.0	$0.10*$	243	24.3	0.00	10.0
60 69	19.9	218	0.04	26.5	26.5	0.00	6.3
70 79	22.0	16.6	$0.15*$	17.7	17.7	0.00	12.9
$80+$	22.9	12.8	$0.30*$	14.8	14.8	0.00	6.3
Male sex (%)	52.4	56.6	0.08	59.6	59.6	0.00	46.7
Comorbidities ^b (N)	5.5	3.2	$0.31*$	4.1	34	0.09	1.1
Variant subtype ^c							
N501Y	\bullet	91.0	\sim	\bullet	91.0	\blacksquare	913
E484K	÷.	9.0	\blacksquare	\mathbf{r}	9.0	ä,	89
Rurality (%)							
Large urban	72.0	84.2	$0.34*$	83.5	843	0.02	84.0
Moderate	17.2	9.1	$0.28*$	10.6	9.1	0.05	92
Small/ medium	4.6	4.6	0.00	36	4.2	0.03	58
Rural	6.2	2.0	$0.30*$	2.3	2.3	0.00	1.0
Income quintile (%)							
Lowest income quintile	37.8	31.8	$0.13*$	36.1	36.1	0.00	17.8
Second income quintile	19.4	21.5	0.05	20.2	20.2	0.00	26.0
Third income quintile	21.3	19.6	0.04	21.1	21.1	0.00	14.7
Fourth income quintile	10.1	15.4	$0.15*$	12.2	12.2	0.00	26.0
Highest income quintile	11.3	11.6	0.01	10.4	10.4	0.00	15.5
Week of detection (mean)	8.9	11.6	$1.27*$	11.3	11.6	0.11	11.6

Table 2: Characteristics of all infected subjects with a hospital admission included in cohort 2

Table 2. Characteristic of hospitalised study subjects (cohort 2). $^{\rm a}$ Cohort includes all subjects included in cohort 1 with a valid hospital admission on record. $^{\rm b}$ Total number of comorbidities. Variant subtypes are non mutually exclusive. ^d Characteristics of VOC-exposed subjects excluded from the matched cohort analysis. Subjects were matched 1:3 with replacement using nearest neighbour matching using a combination of hard and propensity score matching with caliber of 0.25 of the standard deviation of the logit of the propensity score. *Bold indicates standardized differences >0.1. Abbreviations: VOC: Variant of concern; SD: standardized differences.

Table 3: Matched cohort analysis of VOC-attributable hospital admission and mortality

Table 3. Table showing outcomes for study subjects before and after matching for the two cohort of patients evaluated in the study. Cohort 1 consist of all COVID-19 cases with a VOC status from January 1 to April 9, 2021 in Ontario, Canada, excluding long-term care residents. Cohort 2 consist of a subset of subjects included in cohort 1 with a hospital admission.^a Attributable outcomes are determined using conditional logistic regression stratified on the matched sets for binary outcomes.^b Supplemental analysis: ICU-related outcomes are underreported by 45% in the CCM dataset and should be interpreted with caution. Consitivity analysis was restricted to subjects with resolved infection outcome on record to account for right censoring. Abbreviations: VOC: variant of concern; CI: confidence interval; OR: odds ratio; MD: mean difference; ICU: intensive care unit.

Tables and Figures

Table 4. ^a The cohort consist of all cases with a VOC status excluding unresolved infection and long-term care resident Table 4. The conori consist of an cases with a voc status excluding unesolved intection and long term care residents.
"Attributable outcomes are determined using conditional logistic regression stratified on the matched se variant of concern; ICU: intensive care unit; CI: confidence interval; OR: odds ratio.

	Cohort prior to matching			Matched cohort			Unmatched subjects ^d
COHORT 1^ª	Non VOC	VOC	SD	Non-VOC	VOC	SD	VOC
	$N = 14,242$	$N = 17,835$		$N = 14,082$	$N = 17,742$		$N = 93$
Age in years (mean)	38.1	35.3	$0.13*$	35.2	35.1	0.00	71.7
Age groups (%)							
< 10	8.2	9.8	0.05	9.9	9.9	0.00	0 ₀
10 19	14.4	16.8	0.06	16.9	16.9	0.00	0.0
20 29	17.6	18.5	0.03	18.6	18.6	0.00	0.0
30-39	14.5	14.1	0.01	14.1	14.1	0.00	0.0
40 49	13.4	14.0	0.02	14.1	14.1	0.00	0.0
50-59	14.0	12.8	0.04	12.8	12.8	0.00	0.0
60 69	9.4	76	0.07	7.5	7.5	0.00	86
70 79	4.95	39	0.05	38	38	0.00	22.6
$80+$	3.7	26	0.07	2.4	2.4	0.00	32.3
Male sex (%)	51.0	52.0	0.02	52.0	52.0	0.00	46.2
Comorbidities ^b (%)	1.2	0.7	0.06	0.6	0.7	0.01	3.2
Variant subtype ^c							
N501Y	91.3	\sim	ω	91.3	\sim	\sim	\sim
E484K	6.3	ω	ω	6.3	\sim	÷.	
Rurality (%)							
Large urban	65.5	75.4	$0.23*$	76.5	75.3	0.03	100.0
Moderate	18.2	12.8	$0.16*$	12.3	12.9	0.02	0.0
Small/ medium	90	79	0.04	7.0	7.9	0.03	0.0
Rural	7.3	14.0	0.17	4.2	4.0	0.01	0.0
Income quintile (%)							
Lowest income quintile	23.3	19.5	$0.10*$	19.6	19.6	0.00	4.3
Second income quintile	18.3	16.7	0.04	16.5	16.5	0.00	5.5
Third income quintile	20.8	20.4	0.01	20.5	20.5	0.00	86
Fourth income quintile	20.2	25.6	$0.12*$	25.6	25.6	0.00	9.7
Highest income quintile	17.3	17.9	0.01	17.8	17.8	0.00	22.6
Week of detection (mean)	9.3	11.4	$1.02*$	11.3	11.3	0.01	13.7

Supplemental Table 1: Characteristics of study subjects included the sensitivity analysis for cohort 1

Supplemental Table 1. Characteristic of study subjects excluding those with an unresolved infection status on record (cohort 1).⁸ The cohort consist of all cases with a VOC status excluding unresolved infection and long-term care residents. ^b Proportion with 3 or more comorbidities. C Variant subtypes are non mutually exclusive. ^d Characteristics of VOC-exposed subjects excluded from the matched cohort analysis. *Bold indicates standardized differences >0.1. Abbreviations: VOC: Variant of concern; SD: standardized differences.

Supplemental Material

Supplemental Table 2: Characteristics of study subjects included the sensitivity analysis for cohort 2

Supplemental Table 2. Characteristic of hospitalised study subjects excluding those with an unresolved infection status on record (cohort 2).³ Cohort includes all subjects include in cohort 1 with a valid hospital admission on record excluding unresolved infection and long-term care residents. ^b Total number of comorbidities with. C Variant subtypes are non mutually exclusive.^d Characteristics of VOC-exposed subjects excluded from the matched cohort analysis. *Bold indicates standardized differences >0.1. Abbreviations: VOC: Variant of concern; SD: standardized differences.